Zhu Xiao-Jing, Wei Jin-Kai, Zhang Cong-Min
Department of Pediatrics, Baoding First Central Hospital, Baoding, Hebei, China.
J Int Med Res. 2019 Nov;47(11):5732-5739. doi: 10.1177/0300060519870947. Epub 2019 Sep 13.
This study aimed to evaluate endothelial microparticles (EMPs) as a potential prognostic marker in hemolytic disease of the Chinese neonate.
We compared 29 newborns with ABO hemolytic disease of the newborn (ABO HDN), 22 newborns with Rh HDN, and 21 healthy newborns with matched mother and infant blood groups (controls). Markers of hemolysis and von Willebrand factor antigen (vWF Ag) were analyzed. EMP (CD144+) levels were measured before and after therapy.
vWF Ag and pretherapy EMP levels were higher in the ABO HDN and Rh HDN groups than in the control group. Additionally, vWF Ag and pretherapy EMP levels were significantly higher in the ABO HDN group than in the Rh HDN group. Posttherapy EMP levels were decreased compared with pretherapy levels in the ABO HDN and Rh HDN groups. Moreover, hemoglobin and indirect bilirubin levels were independently correlated with pretherapy EMP levels in the ABO HDN group.
Our findings indicate that EMP measurement in neonates with HDN may provide a novel method of monitoring possible severe vascular dysfunction in patients in China. An external validation in larger datasets is necessary for further study.
本研究旨在评估内皮微粒（EMPs）作为中国新生儿溶血病潜在预后标志物的价值。
我们比较了29例患有新生儿ABO溶血病（ABO HDN）的新生儿、22例患有Rh溶血病（Rh HDN）的新生儿以及21例母婴血型匹配的健康新生儿（对照组）。分析了溶血标志物和血管性血友病因子抗原（vWF Ag）。在治疗前后测量EMP（CD144+）水平。
ABO HDN组和Rh HDN组的vWF Ag和治疗前EMP水平高于对照组。此外，ABO HDN组的vWF Ag和治疗前EMP水平显著高于Rh HDN组。ABO HDN组和Rh HDN组治疗后的EMP水平较治疗前降低。此外，ABO HDN组的血红蛋白和间接胆红素水平与治疗前EMP水平独立相关。
我们的研究结果表明，检测HDN新生儿的EMP可能为监测中国患者潜在的严重血管功能障碍提供一种新方法。需要在更大的数据集中进行外部验证以进一步研究。
